The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.
Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.
We built ioCells to solve this challenge.
Developed on our platform, and powered by opti-ox technology, ioCells are human cells deterministically programmed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.
ioCells are for research use only.
ioWild Type Cells
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
CRISPR-Ready ioCells
CRISPR-Ready ioCells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
Custom Cell Development
We provide our partners with the ability to develop and access any human cell type at scale, removing the experimental burden of cell models that are not translatable, scalable or an accurate representation of disease
Consistent
Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.
Cost-effective
ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.
Defined
Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.
Easy-to-use
ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.
Quick
Deterministically programmed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.
Scalable
With opti-ox technology we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River
Dr Mariangela Iovino
Senior Group Leader | Biology Discovery | Charles River
Rodney A. Bowling Jr, PhD
Co-Founder & Chief Scientific Officer | Everlum Bio
Every ioCell is powered by opti-ox.
Using opti-ox, populations of stem cells are precisely and consistently programmed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research.
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Ritsma, et al
Charles River Laboratories & bit.bio
2022
Raman, et al
bit.bio
2022
Dr Deepak Srivastava | King’s College London
Dr Marijn Vlaming | Head of Biology, et al.
Charles River & bit.bio
Dr Marijn Vlaming | Head of Biology
Charles River
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Talk at ELRIG CRISPR in Drug Discovery
Lachize, et al
Courtesy of Charles River Laboratories
2020
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Dr Thomas Moreau | Head of Research | bit.bio
Talk at ELRIG Drug Discovery Digital
Davenport A, Frolov T & Kotter M
Drug Discovery World
2020
Pawlowski M et al
Stem Cell Reports
2017